Primary Neuroendocrine Carcinoma of the Anal Canal with Cancer Genome Profiling
Primary neuroendocrine carcinoma (NEC) of the anal canal is a rare, highly malignant tumor with a poor prognosis. Despite the standard first-line treatment with etoposide or irinotecan combined with cisplatin, effective second-line therapies are lacking. In 2019, Japan approved cancer genome profiling (CGP) tests for solid tumors to enhance genomic understanding. We present the case of a 79-year-old woman with NEC of the anal canal, treated with etoposide, carboplatin, and amrubicin. As Post-standard therapy, CGP suggested pemigatinib, a tyrosine kinase inhibitor; however, the patient died before receiving it. This case highlights the potential of personalized medicine to improve outcomes in such cases.
Authors
- Tomoyuki Ohno
- Tomohiro Ueda (ORCID: https://orcid.org/0000-0002-9611-5691)
- Tasuku Hara (ORCID: https://orcid.org/0000-0002-1751-6201)
- Naohisa Yoshida (ORCID: https://orcid.org/0000-0001-6167-9705)
- Eiichi Konishi (ORCID: https://orcid.org/0000-0002-7122-2271)
- Nobuaki Fuji (ORCID: https://orcid.org/0000-0002-0886-0510)
- Akiko Shibuya (ORCID: https://orcid.org/0000-0002-4861-893X)
- Seiya Sugeta
- Yasutaka Morimoto
- Tomoki Nakajima (ORCID: https://orcid.org/0009-0003-7733-0921)
- Ryuichi Morita
- Juichiro Yoshida (ORCID: https://orcid.org/0000-0002-2685-5993)
Institutions
- Kyoto Prefectural University of Medicine (JP)
- Fukui-ken Saiseikai Hospital (JP)
- Japanese Red Cross Society Kyoto Daini Hospital (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2024-10-10
- DOI
- https://doi.org/10.2169/internalmedicine.4289-24
- Primary Topic
- Colorectal and Anal Carcinomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00